Jason Harrison, MD
Internal Medicine · Mobile, ALNPI 1366708661
Payments from drug & device makers
Across 452 payments — averaging $15.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$3K
- AbbVie$1K
- GSK$340
- Pfizer$267
- Lilly USA, LLC$204
- Sumitomo Pharma America, Inc.$174
- plus $1K from 27 others
What the payments were for
- Food & beverage$6,782100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 220 | $3,027 |
| AbbVie(2 entities) | 95 | $1,478 |
| GSK | 23 | $340 |
| Pfizer | 17 | $267 |
| Lilly USA, LLC | 13 | $204 |
| Sumitomo Pharma America, Inc. | 11 | $174 |
| Johnson & Johnson | 10 | $152 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $140 |
| Bayer | 6 | $122 |
| Astellas Pharma US Inc | 6 | $93 |
| Novartis | 5 | $92 |
| Biohaven Pharmaceuticals, Inc. | 4 | $67 |
| AstraZeneca | 3 | $60 |
| Sanofi-aventis U.S. LLC | 3 | $60 |
| Abbott | 3 | $58 |
| Mylan Specialty L.p. | 3 | $56 |
| Axsome Therapeutics, Inc. | 2 | $45 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $37 |
| Phathom Pharmaceuticals, Inc. | 1 | $33 |
| Esperion Therapeutics, Inc. | 2 | $32 |
| Amgen | 2 | $28 |
| Idorsia Pharmaceuticals US Inc | 2 | $27 |
| Insulet Corporation | 1 | $23 |
| Ardelyx, Inc. | 1 | $21 |
| Genentech USA, Inc. | 1 | $18 |
| Dexcom, Inc. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| Medtronic | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Exact Sciences | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $13 |
How this compares
$6,782 in reported general payments places this provider in the 85th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 345 | $458,593 |
| OzempicSemaglutide | 271 | $387,032 |
| RybelsusSemaglutide | 90 | $148,176 |
| JardianceEmpagliflozin | 103 | $134,917 |
| FarxigaDapagliflozin Propanediol | 133 | $128,524 |
| LinzessLinaclotide | 98 | $110,152 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 111 | $106,824 |
| EliquisApixaban | 109 | $106,637 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 15 | $58,618 |
| Tresiba Flextouch U-200Insulin Degludec | 67 | $55,880 |
| BelsomraSuvorexant | 78 | $53,692 |
| XareltoRivaroxaban | 31 | $47,677 |
| TrulicityDulaglutide | 32 | $43,720 |
| JanuviaSitagliptin Phosphate | 38 | $42,038 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 53 | $40,945 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Wegovy | $3,027 | $560,491378 claims |
| Lilly USA, LLCMounjaro, Trulicity | $204 | $502,313377 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Stiolto Respimat, Spiriva Respimat, Synjardy | $17 | $272,455259 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $60 | $146,917168 claims |
| PfizerEliquis, Nurtec Odt | $267 | $136,394126 claims |
| AbbVieLinzess | $1,478 | $110,15298 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $340 | $72,727107 claims |
| Johnson & JohnsonXarelto | $152 | $47,67731 claims |
| Astellas Pharma US IncMyrbetriq | $93 | $27,21131 claims |
| NovartisEntresto | $92 | $13,56511 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $174 | $10,99320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Mobile
- Harry StuddardMobile$12.9M
- Thomas McKelveyMobile$365K
- Mary HonkanenMobile$302K
- Bobby WrightsMobile$89K
- Rahel AzizMobile$67K
- Jamie CaudillMobile$52K
- Thomas GarthMobile$48K
- Lin LiMobile$45K
- Edward CarlosMobile$26K
- Donald SandersMobile$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.